Inhibitors of Protein-Processivity Factor

Summary Harvard investigators have discovered that Pol interacts with a processivity factor at a site that is distinct from sites of normal interaction between known Pol family members and other cellular factors. Unlike most protein-protein interactions, the target site is uniquely suited to small molecule drug discovery. Structure-based methods of designing and screening candidate drugs aimed at disrupting Pol processivity factor binding at this target site are fully disclosed. Treatment of viral infection using drugs developed according to these methods is additionally encompassed by the invention.

Applications Herpesvirus infection underlies a broad range of pathological conditions requiring long-term treatment in affected individuals. Genital herpes and sight-threatening ocular infections result from the infection of immunocompetent adults with herpes simplex virus (HSV), while human cytomegalovirus (CMV) produces diseases in immunosuppressed adults and transplant patients and is a major cause of birth defects. 'Productive' infection relies upon efficient replication of the viral genome in the affected host. Herpesvirus DNA replication is enhanced by the interaction of virally-encoded processivity factors with host cell polymerase (Pol) molecules. The disclosed invention is applicable to the design of a broad class of antiviral agents. For Further Information Please Contact the Director of Business Development Katie Gordon Email: [email protected] Telephone: (617) 432-0920

Inventor(s): Coen, Donald M

Type of Offer: Licensing



Next Patent »
« More Chemistry Patents
« More Pharmaceutical Patents

Share on      


CrowdSell Your Patent